The DOI matches its Crossref record; 218 of the 218 references it cites were found in a registry or an index.
Redox Homeostasis and Cellular Antioxidant Systems: Crucial Players in Cancer Growth and Therapy
Open accessAbstract
Reactive oxygen species (ROS) and their products are components of cell signaling pathways and play important roles in cellular physiology and pathophysiology. Under physiological conditions, cells control ROS levels by the use of scavenging systems such as superoxide dismutases, peroxiredoxins, and glutathione that balance ROS generation and elimination. Under oxidative stress conditions, excessive ROS can damage cellular proteins, lipids, and DNA, leading to cell damage that may contribute to carcinogenesis. Several studies have shown that cancer cells display an adaptive response to oxidative stress by increasing expression of antioxidant enzymes and molecules. As a double‐edged sword, ROS influence signaling pathways determining beneficial or detrimental outcomes in cancer therapy. In this review, we address the role of redox homeostasis in cancer growth and therapy and examine the current literature regarding the redox regulatory systems that become upregulated in cancer and their role in promoting tumor progression and resistance to chemotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Items 201–218 of 218
Marengo, B., Ciucis, C. D. D., Ricciarelli, R., Passalacqua, M., Nitti, M., Zingg, J.-M., Marinari, U., Pronzato, M., & Domenicotti, C. (2011) · PLoS ONE · doi:10.1371/journal.pone.0014661 · Cited by 31
Self-citationPeroxiredoxin 3 is resistant to oxidation-induced apoptosis of Hep-3b cells
Wang, Y., Li, L., Liu, C.-H., Hong, S., & Zhang, M.-J. (2013) · Clinical & Translational Oncology · doi:10.1007/s12094-013-1117-y · Cited by 30
Li, G., Liang, H., Liao, B., Zhang, L., Ni, Y.-A., Zhou, H., Zhang, E., Zhang, B., & Chen, X. (2015) · PubMed · Cited by 30
Pharmacology of a mimetic of glutathione disulfide, NOV-002
Townsend, D. M., & Tew, K. D. (2008) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2008.08.019 · Cited by 29
Initial testing of JNJ‐26854165 (Serdemetan) by the pediatric preclinical testing program
Smith, M. A., Gorlick, R., Kolb, E. A., Lock, R., Carol, H., Maris, J. M., Keir, S. T., Morton, C. L., Reynolds, C. P., Kang, M. H., et al. (2012) · Pediatric Blood & Cancer · doi:10.1002/pbc.23319 · Cited by 26
HOU, J., Cui, A., Song, P., Hua, H. M., Luo, T. L., & Jiang, Y. (2014) · Molecular Medicine Reports · doi:10.3892/mmr.2014.2736 · Cited by 24
Motexafin Gadolinium for the Treatment of Metastatic Renal Cell Carcinoma: Phase II Study Results
Amato, R. J., Jac, J., & Hernandez-McClain, J. (2008) · Clinical Genitourinary Cancer · doi:10.3816/cgc.2008.n.011 · Cited by 23
Redox Regulation of NF-κB: From Basic to Clinical Research
Antunes, F., & Han, D. (2009) · Antioxidants and Redox Signaling · doi:10.1089/ars.2009.2659 · Cited by 22
Baker, A. F., Landowski, T. H., Dorr, R. T., Tate, W. R., Gard, J. M. C., Tavenner, B. E., Dragovich, T., Coon, A., & Powis, G. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0873 · Cited by 21
A phase I study of imexon plus gemcitabine as first-line therapy for advanced pancreatic cancer
Cohen, S. J., Zalupski, M. M., Modiano, M., Conkling, P., Patt, Y. Z., Davis, P., Dorr, R. T., Boytim, M. L., & Hersh, E. M. (2009) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-009-1162-y · Cited by 20
Mechanisms of inactivation of hepatocyte protein kinase C isoforms following acute ethanol treatment
Domenicotti, C., Paola, D., Vitali, A., Nitti, M., Cottalasso, D., Melloni, E., Poli, G., Marinari, U. M., & Pronzato, M. A. (1998) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(98)00079-3 · Cited by 19
Self-citationCorrelates of imexon sensitivity in human multiple myeloma cell lines
Samulitis, B. K., Landowski, T. H., & Dorr, R. T. (2005) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190500266210 · Cited by 18
PKCα promotes generation of reactive oxygen species via DUOX2 in hepatocellular carcinoma
Wang, J., Shao, M., Liu, M., Peng, P., Li, L., Wu, W., Wang, L., Duan, F., Zhang, M., Song, S., et al. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.06.021 · Cited by 17
Peroxiredoxin V: A candidate breast tumor marker of population specificity
Elamin, A., Zhu, H., Hassan, A. M. E., Xu, N., & Ibrahim, M. E. (2013) · Molecular and Clinical Oncology · doi:10.3892/mco.2013.91 · Cited by 16
Pronzato, M. A., Domenicotti, C., Biasi, F., Chiarpotto, E., Cottalasso, D., Viotti, P. L., Melloni, E., Marinari, U. M., & Poli, G. (1990) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(90)90835-b · Cited by 15
Self-citationHallak, M., Win, T., Shpilberg, O., Bittner, S., Granot, Y., Levi, I., & Nathan, I. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07867.x · Cited by 13
Ramanathan, R. K., Fakih, M., Mani, S., Deutsch, M., Perez, R. P., Ritter, M. A., Eiseman, J. L., Ivy, S. P., Trump, D. L., Belani, C. P., et al. (2005) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-005-0071-y · Cited by 13
GSH loss per se does not affect neuroblastoma survival and is not genotoxic
Marengo, B., Balbis, E., Patriarca, S., Ciucis, C. D., Furfaro, A. L., Nitti, M., Marinari, U. M., Pronzato, M. A., Traverso, N., & Domenicotti, C. (2008) · International Journal of Oncology · doi:10.3892/ijo.32.1.121 · Cited by 8
Self-citation
Cited by
ROS and the DNA damage response in cancer
Srinivas, U. S., Tan, B. W. Q., Vellayappan, B. A., & Jeyasekharan, A. D. (2019) · Redox Biology · doi:10.1016/j.redox.2018.101084 · Cited by 2,144
“Secondly, ROS has a dose dependent effect on activity of proteins leading to differential downstream outcomes [140], which are”
BackgroundNRF2 and the Hallmarks of Cancer
Rojo de la Vega, M., Chapman, E., & Zhang, D. D. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.022 · Cited by 1,672
ROS signaling under metabolic stress: cross-talk between AMPK and AKT pathway
Zhao, Y., Hu, X., Liu, Y., Dong, S., Wen, Z., He, W., Zhang, S., Huang, Q., & Shi, M. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0648-1 · Cited by 735
Emerging roles of lipid metabolism in cancer metastasis
Luo, X., Cheng, C., Tan, Z., Li, N., Tang, M., Yang, L., & Cao, Y. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0646-3 · Cited by 677
Metabolic programming and immune suppression in the tumor microenvironment
Arner, E. N., & Rathmell, J. C. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.01.009 · Cited by 668
Metadata
- Authors
- Marengo, B., Nitti, M., Furfaro, A. L., Colla, R., Ciucis, C. D., Marinari, U. M., Pronzato, M. A., Traverso, N., & Domenicotti, C.
- Venue
- Oxidative Medicine and Cellular Longevity
- Publisher
- Wiley
- Published
- 2016-01
- Volume
- 2016
- Issue
- 1
- Pages
- 6235641-6235641
- ISSN
- 1942-0994 (ISSN-L)
- 1942-0900
- OpenAlex
- W2468344619
- Cited by
- 319
- References
- 218
- FWCI
- 13.24
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.